PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Evan A. Stein et al.|The Lancet|2014Cited by 750
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeJoseph L. Witztum, Éric Bruckert, Daniel Gaudet et al.|New England Journal of Medicine|2019Cited by 663
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin IntoleranceErik S.G. Stroes, Michael Rocco, Éric Bruckert et al.|Journal of the American College of Cardiology|2014Cited by 527